Lord Abbett & CO. LLC Decreases Stock Holdings in Cellebrite DI Ltd. $CLBT

Key Points

• Lord Abbett & CO. LLC has reduced its stake in Cellebrite DI Ltd. by 28.7%, now holding 520,804 shares after selling 209,535 shares in the first quarter.
• Analysts are optimistic about Cellebrite DI's future, with 8 analysts rating the stock as a buy and a consensus target price of $21.00, despite recent adjustments in individual price targets from firms like Lake Street Capital and JPMorgan Chase & Co..
• Cellebrite's latest earnings report showed a quarterly EPS of $0.12, surpassing analyst expectations and marking an 18.4% revenue increase compared to the previous year.

Lord Abbett & CO. LLC lowered its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 28.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 520,804 shares of the company's stock after selling 209,535 shares during the quarter. Lord Abbett & CO. LLC owned about 0.22% of Cellebrite DI worth $10,119,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. HighTower Advisors LLC grew its holdings in shares of Cellebrite DI by 16.3% in the first quarter. HighTower Advisors LLC now owns 14,485 shares of the company's stock valued at $281,000 after purchasing an additional 2,029 shares during the period. Nuveen LLC purchased a new position in shares of Cellebrite DI in the first quarter valued at approximately $15,031,000. Entropy Technologies LP purchased a new position in shares of Cellebrite DI in the first quarter valued at approximately $660,000. Polen Capital Management LLC boosted its stake in shares of Cellebrite DI by 47.1% in the first quarter. Polen Capital Management LLC now owns 14,849 shares of the company's stock valued at $289,000 after purchasing an additional 4,754 shares during the period. Finally, Invesco Ltd. raised its holdings in Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after acquiring an additional 1,811,757 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Trading Down 2.5%

Shares of NASDAQ:CLBT traded down $0.3890 during midday trading on Wednesday, hitting $15.4110. 1,030,855 shares of the stock were exchanged, compared to its average volume of 1,669,871. The stock has a market cap of $3.69 billion, a P/E ratio of -20.39, a PEG ratio of 3.20 and a beta of 1.27. Cellebrite DI Ltd. has a twelve month low of $13.10 and a twelve month high of $26.30. The company has a 50 day moving average price of $14.96 and a 200-day moving average price of $17.67.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business's revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on CLBT. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday. JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Finally, Lake Street Capital lowered their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Cellebrite DI presently has an average rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.